Medicinal chemistry

The group takes on medicinal chemistry projects. Past activity includes development of antifungal agents and inhibitors of the epidermal growth factor receptor (EGFR). Current work focus on inhibitors of the colony stimulating factor 1 receptor (CSF1R). Potent and selective inhibitors of this tyrosine kinase could offer treatment for several forms of cancer and inflammation diseases. Molecular docking, dynamics and Fragment-growth are used to provide working hypothesis and to explain the binding mode of our new ligands. Druglike properties are monitored by common metrics as Lipinski’s rule of five, LE, LLE, BEI, SEI and LELP. Kinase profiling is performed by CRO’s, while cell and ADME studies are done by both university collaborators and CRO’s.

Organic chemistry

At the heart of our activity is the organic chemistry lab. These are well equipped for performing modern organic synthesis. Our aim is to develop scalable divergent routes giving access to a range of products.

Compounds are isolated and purified by conventional methods and characterised using HPLC, NMR and mass spectroscopic methods.